According to reports from Business Standard, Symbiotec Pharmalab reported a 53.01% year-on-year decline in consolidated net profit to ₹14.06 crore for Q1 FY27, compared to ₹29.92 crore in Q1 FY26. Despite this profit decline, the company achieved a 7.37% rise in revenue from operations to ₹218.15 crore compared to ₹203.17 crore in the previous year, indicating mixed operational performance during the quarter. As per Moneycontrol, the latest consolidated quarterly numbers show the top line growing 7 percent YoY while net profit nearly halved, highlighting the challenging operating environment faced by the pharmaceutical company.
As reported by Business Standard, the company's reported EBITDA declined by 22.1% year-on-year to ₹45.2 crore while reported EBITDA margin contracted by 800 basis points YoY to 21% in Q1 FY27. Profit before tax stood at ₹17.5 crore, representing a 60.9% decrease from ₹44.8 crore recorded in Q1 FY26, highlighting the significant impact on overall profitability despite revenue growth. The operating profit margin (OPM) compressed to 20.72% from 28.53% in the previous year, reflecting the challenging operating environment. According to Moneycontrol, the company faces key challenges with execution and margin recovery despite having a strong steroid API franchise and ready-to-use CDMO capacity that offer growth potential.
According to Business Standard, the company's net debt as of June 30, 2026 was ₹398 crore. Following the IPO, the net debt stood at ₹326 crore as of September 20, 2026, indicating a reduction in debt levels post-public offering. This debt reduction demonstrates improved financial management following the company's transition to a listed entity.
As reported by Business Standard, the API business delivered steady revenue growth of 6% and EBITDA growth of 9% during the quarter. The company's Complex Injectables segment filed its first ANDA from the Dual Chamber Vial platform this quarter, moving closer to commercialization with plans for a second filing in coming months. In the Biotech - CDMO Services segment, engagement is widening steadily with new customers exploring manufacturing programmes across the company's capabilities. According to Moneycontrol, the company's strong steroid API franchise and ready-to-use CDMO capacity offer growth potential, though execution and margin recovery remain key challenges for unlocking the next leg of growth.
According to Business Standard, the company's scrip rose 0.31% to currently trade at ₹1162 on the BSE. The modest stock movement suggests investor cautiousness following the mixed quarterly results, with the market showing measured response to both the profit decline and revenue growth achievements during the quarter. As per Moneycontrol, the market response reflects investor concerns about the company's ability to execute its growth strategy and achieve margin recovery despite having strong underlying business fundamentals.
